C
KNSA icon

Covestor’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Covestor’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed – – 2534
2025
Q4 		$0 Hold
4
– – ﹤0.01% 2506
2025
Q3 		$0 Sell
4
-8
-67% -$260 ﹤0.01% 2523
2025
Q2 		$0 Sell
12
-6
-33% -$153 ﹤0.01% 2478
2025
Q1 		$0 Buy
18
+5
+38% +$103 ﹤0.01% 2480
2024
Q4 		$0 Buy
13
+2
+18% +$46 ﹤0.01% 2488
2024
Q3 		$0 Buy
+11
New +$268 ﹤0.01% 2472
2024
Q2 		– Sell
-24
Closed – – 2491
2024
Q1 		$0 Sell
24
-29
-55% -$566 ﹤0.01% 2490
2023
Q4 		$1K Sell
53
-63
-54% -$1.03K ﹤0.01% 1991
2023
Q3 		$2K Sell
116
-44
-28% -$741 ﹤0.01% 1828
2023
Q2 		$2K Buy
+160
New +$2.14K ﹤0.01% 1842

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Covestor's KNSA Position: Q1 2026 in Review

Covestor sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 4 shares.

Covestor first reported a position in KNSA in Q2 2023 and held it in 10 quarters. The position peaked at $2K in Q3 2023. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Covestor reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Covestor sold 4 Kiniksa Pharmaceuticals shares in Q1 2026.
  • Covestor first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Covestor's Kiniksa Pharmaceuticals position peaked at $2K in Q3 2023.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.